AN ORAL PHARMACEUTICAL FORMULATION CONTAINING AN EFFECTIVE AMOUNT OF NRC- AN-019 INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHS SUCH AS FORM I, FORM II AND FORM III THEREOF TO IMPROVE THE BIOAVAILABILITY INTENDED FOR SELF-EMULSIFICATION UPON ITS CONTACT WITH THE GASTRO-INTESTINAL FLUID. THE INVENTION ALSO RELATES TO A PROCESS FOR THE PREPARATION OF ORAL SOLUTION CONTAINING NRC- AN-019 IN AN EFFECTIVE CONCENTRATION FOR THE BATTER THERAPY AGAINST CHRONIC MYELOID LEUKEMIA AS BCR-ABL TYROSINE KINASE INHIBITOR AND AGAINST OTHER TUMORS SUCH AS HEAD AND NECK CANCER, PROSTATE CANCER AND THE LIKE
